Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
PCRX Pacira BioSciences Inc
- Stocks
- Healthcare
- NASDAQ: PCRX
Price (delayed)
$24.15
Market cap
$1.12B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.25
Enterprise value
$1.47B
Pacira BioSciences, Inc.is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. The company's long-acting local
Highlights
Pacira BioSciences's gross profit has increased by 9% YoY and by 2.8% QoQ
The company's gross margin rose by 6% YoY and by 2.5% QoQ
The equity has declined by 10% year-on-year but it has increased by 2.6% since the previous quarter
The company's quick ratio has shrunk by 59% YoY
Pacira BioSciences's debt has increased by 9% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.pacira.com
Key stats
What are the main financial stats of PCRX
Market
Valuations
Earnings
Shares outstanding
46.3M
Market cap
$1.12B
Enterprise value
$1.47B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.4
Price to sales (P/S)
1.59
EV/EBIT
N/A
EV/EBITDA
46.97
EV/Sales
2.09
Revenue
$702.77M
Gross profit
$545.45M
Operating income
-$84.59M
Net income
-$103.73M
EBIT
-$50.21M
EBITDA
$31.32M
Free cash flow
$159.4M
Per share
Balance sheet
Liquidity
EPS
-$2.25
EPS diluted
-$2.27
Free cash flow per share
$3.44
Book value per share
$17.26
Revenue per share
$15.19
TBVPS
$24.42
Total assets
$1.59B
Total liabilities
$788.13M
Debt
$636.46M
Equity
$798.54M
Working capital
$445.23M
Debt to equity
0.8
Current ratio
2.41
Quick ratio
1.9
Net debt/EBITDA
11.27
Margins
Efficiency
Dividend
EBITDA margin
4.5%
Gross margin
77.6%
Net margin
-14.8%
Operating margin
-12%
Return on assets
-6.6%
Return on equity
-12.9%
Return on invested capital
-4.1%
Return on capital employed
-3.9%
Return on sales
-7.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PCRX stock price
How has the Pacira BioSciences stock price performed over time
Intraday
-0.98%
1 week
-0.78%
1 month
-6.61%
1 year
-14.33%
YTD
28.18%
QTD
-2.82%
Financial performance
How have Pacira BioSciences's revenue and profit performed over time
Revenue
$702.77M
Gross profit
$545.45M
Operating income
-$84.59M
Net income
-$103.73M
Gross margin
77.6%
Net margin
-14.8%
The company's operating income has shrunk by 181% YoY and by 15% QoQ
PCRX's operating margin has shrunk by 178% YoY and by 14% QoQ
Pacira BioSciences's gross profit has increased by 9% YoY and by 2.8% QoQ
The company's gross margin rose by 6% YoY and by 2.5% QoQ
Price vs fundamentals
How does PCRX's price correlate with its fundamentals
Growth
What is Pacira BioSciences's growth rate over time
Valuation
What is Pacira BioSciences stock price valuation
P/E
N/A
P/B
1.4
P/S
1.59
EV/EBIT
N/A
EV/EBITDA
46.97
EV/Sales
2.09
Pacira BioSciences's EPS has decreased by 4.7% QoQ
PCRX's P/B is 52% below its 5-year quarterly average of 2.9 but 8% above its last 4 quarters average of 1.3
The equity has declined by 10% year-on-year but it has increased by 2.6% since the previous quarter
The price to sales (P/S) is 57% lower than the 5-year quarterly average of 3.7 but 14% higher than the last 4 quarters average of 1.4
The revenue has grown by 3.1% YoY
Efficiency
How efficient is Pacira BioSciences business performance
Pacira BioSciences's ROIC has plunged by 145% YoY and by 8% from the previous quarter
Pacira BioSciences's return on sales has shrunk by 142% YoY and by 8% QoQ
PCRX's ROE is down by 7% since the previous quarter
Pacira BioSciences's ROA has decreased by 4.8% from the previous quarter
Dividends
What is PCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PCRX.
Financial health
How did Pacira BioSciences financials performed over time
The total assets is 101% greater than the total liabilities
The current ratio has plunged by 59% YoY
The company's quick ratio has shrunk by 59% YoY
Pacira BioSciences's debt is 20% less than its equity
Pacira BioSciences's debt to equity has increased by 23% YoY but it has decreased by 2.4% from the previous quarter
The equity has declined by 10% year-on-year but it has increased by 2.6% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.